Wellington Management Group LLP Trims Stake in Insmed Incorporated (NASDAQ:INSM)

Wellington Management Group LLP lessened its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 21.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 752,226 shares of the biopharmaceutical company's stock after selling 210,233 shares during the period. Wellington Management Group LLP owned approximately 0.42% of Insmed worth $51,934,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after acquiring an additional 1,075,796 shares during the period. Darwin Global Management Ltd. grew its holdings in shares of Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after acquiring an additional 2,463,261 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Insmed by 1.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock worth $877,113,000 after acquiring an additional 123,429 shares during the period. Capital International Investors grew its holdings in shares of Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after acquiring an additional 593,206 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Insmed by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after acquiring an additional 273,759 shares during the period.

Analyst Ratings Changes

INSM has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Wells Fargo & Company boosted their price target on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. Truist Financial boosted their price target on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. Finally, Guggenheim reissued a "buy" rating and set a $101.00 price target on shares of Insmed in a report on Tuesday, February 25th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Insmed has an average rating of "Moderate Buy" and an average target price of $96.73.

Insider Buying and Selling at Insmed

In other Insmed news, insider Michael Alexander Smith sold 409 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $65.61, for a total transaction of $26,834.49. Following the sale, the insider now directly owns 91,794 shares in the company, valued at $6,022,604.34. This represents a 0.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Clarissa Desjardins bought 1,130 shares of the business's stock in a transaction dated Wednesday, May 21st. The shares were acquired at an average cost of $66.35 per share, for a total transaction of $74,975.50. Following the purchase, the director now owns 3,025 shares of the company's stock, valued at approximately $200,708.75. The trade was a 59.63% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 134,348 shares of company stock worth $9,265,629 over the last ninety days. Company insiders own 3.00% of the company's stock.

Insmed Price Performance

Shares of NASDAQ:INSM traded up $1.80 during mid-day trading on Monday, reaching $71.53. The stock had a trading volume of 1,545,239 shares, compared to its average volume of 2,098,989. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market cap of $13.03 billion, a P/E ratio of -12.78 and a beta of 0.84. Insmed Incorporated has a 1 year low of $54.71 and a 1 year high of $84.91. The business's 50 day moving average price is $69.60 and its 200 day moving average price is $72.95.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Insmed's quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.06) earnings per share. Research analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.